Brief: Orexo Maintains Guidance For 2024
July 17 (Reuters) - Orexo AB ORX.ST :
* THERE WILL BE A DELAY IN ORIGINAL TIME GUIDANCE
* WE MAINTAIN GUIDANCE FOR 2024, BUT WE SEE SOME RISK TO
ZUBSOLV
REVENUE GUIDANCE WITH WHOLESALERS INVENTORY ADJUSTMENT IN Q1
Source text for Eikon: ID:nWkr8rG4Yj
Further company coverage: ORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Orexo AB
See all newsBrief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Pre-Clinical Data For Nasal Atipamezole Using Amorphox Technology
Brief: Orexo AB Reports Q1 2026 Net Revenue Of Sek 5.0 Million
Sweden's Orexo Q1 revenue drops, net loss widens